Lakewood-Amedex Shares Begin Trading on Nasdaq Today
Lakewood-Amedex Biotherapeutics announced that shares of the company's common stock began trading today on the Nasdaq Capital Market under the ticker symbol "LABT". "We plan to initiate a Phase 2a clinical trial in iDFU shortly," stated Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research and Development. "Close to 40 million people in the US live with diabetes, and around one-third will develop a DFU in their life, of which about 50% will be infected at some point. Additionally, numerous patients experience more than one of these events in their life, and antibiotic-resistant bacterial strains are a major concern for the treatment of these patients. We look forward to accelerating our work targeting this major unmet need."
